Manulife Connect Cambodian Customer to Award-Winning Multi-Cancer Screening in Singapore
Manulife is providing customers with access to the Multi-Cancer Detection (MCD) test* as part of its focus on longevity through a partnership with Guardant Health, a global leader in blood-based cancer testing with over a decade of experience¹. This exclusive partnership marks the first introduction of the Guardant Health MCD test* in Asia and empowers customers with earlier cancer detection capabilities.
The Guardant Health MCD Test*
is intended to detect 10 cancers – bladder, breast, colorectal, esophageal, stomach, liver, lung, ovarian, pancreatic and prostate cancer through a single blood draw.
The MCD Test* by Guardant Health is: |
Scientifically proven, with technology backed by over 1 million oncology blood samples tested |
Innovative - Guradant Health's MCD test has received US FDA breakthrough device designation's |
Thank you for submission!
Oops!
Error 404
Please excuse us
Sorry. We are processing a few things behind the scene. Please try again in a few moments.
But wait, here are some links we think might interest you:
Terms and conditions:
- Lucky draw entries are allocated based on the applicable premium tier.
- Prizes are non-transferable and cannot be exchanged for cash or substituted with any other items.
- The prize will be forfeited if the customer cancels or terminates the policy during the waiting period.
- The prize is valid for one (1) year from the date of award.
- The prize does not include flights, transportation, or any related travel expenses.
- Winners whose policies are within the 21-day free-look period will only be eligible to receive the MCD test after the free-look period has ended, provided that the policy remains active.
- Manulife reserves the right to amend these terms and conditions at any time without prior notice.